Strategies for navigating loss of exclusivity (LOE) in pharma

In the pharmaceutical industry, the end of a product’s patent protection, known as the loss of exclusivity (LOE), marks a significant turning point. It is a period fraught with challenges as companies face the entry of generic competitors to the market, which can drastically reduce market share and revenue.

Understanding the dynamics of loss of exclusivity in pharma, and particularly the so-called ‘patent cliff’, is essential for companies to navigate this phase successfully.

In this blog, we explore:

• What loss of exclusivity (LOE) is
• The concept of the pharmaceutical patent cliff
• The challenges faced as products near the end of exclusivity
• Strategies for defending market share in this critical period

What is loss of exclusivity?

Loss of exclusivity occurs when a pharmaceutical product’s patent protection expires, opening the market to generic competitors. Patents give companies exclusive rights to sell a drug for a set period, typically 20 years from the date of filing. However, this period includes the time it takes for clinical trials and regulatory approval, so the effective market exclusivity is often much shorter. Once the patent expires, generic manufacturers can produce and sell cheaper versions of the drug, which leads to a significant drop in sales for the original product.

What is the pharmaceutical patent cliff?

The pharmaceutical patent cliff refers to a dramatic revenue drop that occurs when several major drugs lose their patent protection around the same time. This phenomenon can have a profound impact on a pharmaceutical company’s financial health. A historical example of the pharmaceutical patent cliff from the early 2010s saw blockbuster drugs like Lipitor and Plavix losing their exclusivity. This led to a significant reduction in revenue for their manufacturers. More recently, AbbVie’s Humira lost exclusivity in 2023 after generating $18.6 billion in U.S. revenue the prior year. This left an opportunity for 9 biosimilars to enter the market in direct competition. The term ‘pharmaceutical patent cliff’ conveys the image of a sudden drop, representing the rapid decline in sales as generics gain market share. This period can be especially challenging for companies that have relied on blockbuster drugs. However, it also offers an opportunity to rethink market strategies, develop innovations, and explore ways to continue delivering value to patients and healthcare systems.

Typical revenue trajectory of a branded medicine before/after LOE

Challenges for companies facing loss of exclusivity

When a product approaches the end of its patent protection, pharmaceutical companies face several significant challenges:

1. Revenue erosion

Pharmaceutical companies face significant revenue erosion after losing exclusivity, as generics or biosimilars enter the market and reduce sales. For example, AbbVie’s Humira saw global sales decline 32% in the first year after its 2023 loss of exclusivity. This impact extended company-wide: AbbVie’s global net revenues fell 6% in 2023. This pattern of revenue erosion forces companies to explore strategies like creating generics themselves, or maximizing value before exclusivity ends.

2. Increased competition

With the entry of generics, the market becomes more competitive. The original brand may need to adjust pricing strategies to remain competitive, which can affect profit margins. In some cases, the market becomes saturated with multiple generics, intensifying the pressure.

3. Market share decline

Generic drugs often capture a significant portion of the market shortly after launch. This leads to a rapid shift in market dynamics.

4. Complex supply chains

For biologics and other complex therapies, maintaining supply chain integrity is crucial. These products often require sophisticated manufacturing processes and cold-chain logistics. This can present challenges for originators in ensuring consistent supply at a lower scale.

5. Specialized markets

Many of the drugs approaching loss of exclusivity today are specialized therapies, such as targeted treatments for rare diseases or biologics. These therapies serve smaller patient populations, requiring tailored approaches to maintain market presence.

6. AI driven ‘me-too’ proliferation

A newer pressure is reshaping the post-loss of exclusivity landscape: the rapid adoption of AI in drug discovery. While AI holds genuine promise for accelerating truly novel therapies, it also lowers the barrier to producing fast-follower molecules that target the same validated mechanisms as established blockbusters.

As more competitors reach a therapeutic class with marginal differentiation, originators face a market that fragments earlier and more aggressively than the traditional generic timeline alone would suggest. The result is compounded pressure on the pharmaceutical cliff. Mechanistically similar branded alternatives can erode share before exclusivity even ends, and once it does, the market crowds further with generics or biosimilars.

Loss of exclusivity strategy: how to defend market share

Pharmaceutical companies need to adopt a loss of exclusivity strategy to maintain market presence as products approach the end of exclusivity. Three fundamental strategies companies should consider are:

1. Research and development solutions

By exploring new therapeutic uses or seeking additional protections, like pediatric exclusivity, companies can extend the life of products or therapies. This allows them to continue serving patients while further developing the product’s potential benefits.

Additionally, companies can build on the success of their original product by introducing improved formulations, like extended-release versions, or even transitioning the drug to over-the-counter status. These enhancements help maintain the product’s relevance and expand its reach.

2. Commercial solutions

Launching branded generics or licensed versions of the original product enables companies to diversify and compete in the generic space – while still offering trusted, high-quality treatments. Developing patient-centric programs, such as those that improve access, adherence, and outcomes, creates added value beyond the medication itself.

Companies can work closely with payers to offer value-based agreements, rebates, or outcome-driven pricing models. This collaborative approach highlights the full value of the product. The focus shifts to patient outcomes, clinical effectiveness, and long-term satisfaction, rather than price alone.

3. Execution tactics

Omni-channel approaches play a key role in ensuring consistent and personalized communication, allowing companies to deliver value-driven messages across multiple platforms.

How to implement a loss of exclusivity strategy

A loss of exclusivity strategy should be implemented with an omni-channel approach as follows:

• Extending a product’s life through new indications or formulations requires clear communication of these innovations. An omni-channel approach ensures stakeholders receive research findings in engaging formats, whether through webinars, reports, or interactive presentations. This makes complex data more accessible and digestible.
• Enhancing existing products, like developing extended-release versions, needs strong messaging to highlight their clinical benefits. Omni-channel loss of exclusivity strategies ensures this message reaches providers, regulators, and patients through tailored channels, making research findings more impactful.
• Diversifying by launching branded or licensed generics requires clear differentiation in the market. Omni-channel communication ensures consistent messaging across multiple platforms, highlighting the quality and trust in these products to all stakeholders, from payers to patients.
• Patient-centric programs create significant value, but effective communication is key. Omni-channel strategies allow companies to engage patients and providers through various platforms, ensuring that support programs are clearly understood and easily accessible.
• Collaboration with payers relies on showcasing value-based agreements effectively. Omni-channel marketing allows for personalized presentations that meet payer needs, delivered through flexible channels like remote meetings or digital tools.

Omni-channel marketing engages stakeholders across multiple touchpoints. It ensures they receive the right information through the right channels, whether via digital platforms or direct engagements, reinforcing the product’s value in a competitive market. Interactive tools offer personalized content that resonates with providers, payers, and patients.

Leveraging digital tools for optimal omni-channel execution

Today’s stakeholders expect more than static presentations or one-way communication. Effective omni-channel strategies require digital tools that deliver consistent, personalized, and interactive experiences across channels.

Modern platforms should support:

• Multiple content formats, including clinical data, animations, interactive models, and live calculations
• Flexible distribution methods, such as embedded website content, mobile apps, stakeholder portals, and interactive presentations
• Real-time interaction with data, allowing stakeholders to explore scenarios and assess value directly
• Personalized experiences tailored to the needs of healthcare providers, payers, and patients
• Centralized content governance to ensure messaging remains accurate, consistent, and compliant across every touchpoint

These capabilities help companies deliver the right message to the right stakeholder through the right channel. This improves engagement, supports decision-making, and reinforces product value in competitive markets.

Summary and next steps

As pharmaceutical products approach loss of exclusivity, clearly communicating ongoing product value becomes critical to maintaining engagement with healthcare providers, payers, and patients.

This is where platforms like BaseCase play a key role, enabling diverse content distribution and real-time interaction with data. The BaseCase platform ensures that value-driven messages are delivered in an engaging, tailored, and controlled format, enhancing the overall communication experience across every channel.

As competition intensifies post-LOE, the companies that succeed will be those that can distribute value-driven content with precision, agility, and control. By combining centralized content governance with flexible omni-channel delivery, BaseCase helps pharmaceutical organizations strengthen stakeholder engagement, support evidence-based decision-making, and sustain market share throughout the LOE transition.